Haodong Chen

Jan 13, 2024 | biorxiv.org | Jinnan Hu |Cai Jiang |Yu Huang |Haodong Chen

AbstractLiquid biopsy enables identification of low allele frequency (AF) tumor variants and novel clinical applications such as minimum residual disease (MRD) monitoring. However, challenges remain, primarily due to limited sample volume and low read count of low-AF variants. Because of the low AFs, some clinically significant variants are difficult to distinguish from errors introduced by PCR amplification and sequencing.